泽璟制药：注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗（依托泊苷/卡铂）联用获得药物临床试验批准通知书

Core Viewpoint - Zai Jian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its drug ZG006 in combination with PD-1/PD-L1 inhibitors and chemotherapy for small cell lung cancer [1] Group 1: Drug Development - ZG006 (INN name: alveltamig) is a trispecific antibody developed through the company's dual/multi-specific antibody research platform [1] - The drug targets DLL3 on tumor cells and CD3 on T cells, effectively bridging T cells and tumor cells to enhance tumor cell destruction [1] - Preclinical studies have shown significant tumor suppression effects in mouse models, with a notable proportion of tumors completely regressing [1]